Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01431300 · ClinicalTrials.gov registry record · NA

Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants

A NA study of Healthy, sponsored by Duke University.

Completed
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT01431300: Completed NA study of Healthy, sponsored by Duke University.

NCT01431300 is a NA study of Healthy that has completed, run by Duke University. The registered enrollment target is 30 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01431300, a NA study of Healthy, has completed, sponsored by Duke University.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to assess the image quality of Ablavar-enhanced MR angiography of the central veins of the chest, and to determine whether dose reduction can be performed while maintaining image quality. This will be a prospective randomized study, in which healthy volunteers will be recruited to undergo a central veins magnetic resonance angiogram (MRA). They will receive either the FDA-approved dose or a lower dose of Ablavar. Quantitative and qualitative analysis will be performed on the images.

Primary Outcome

Two radiologists assessed imaging quality of each central venous segment for each patient, in order to compare imaging quality between each of the three doses administered. The visualization score for each venous segments was as follows: 1. poor / nondiagnostic 2. adequate 3. good 4. excellent

Conditions Studied

Interventions

  • DRUG gadofosveset

Study Locations (1)

North Carolina

  • Duke University Medical Center - Durham

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2011-08
Est. Completion 2013-07
Phase NA
Duke University

1,725 total trials

What the finished NCT01431300 record still lists

NCT01431300 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which gadofosveset is the first listed.

NCT01431300 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT01431300 about?

NCT01431300 is a clinical study titled "Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants". The purpose of this study is to assess the image quality of Ablavar-enhanced MR angiography of the central veins of the chest, and to determine whether dose reduction can be performed while maintaining image quality. This will be a prospective randomized study, in which healthy volunteers will be re...

What is the current status of trial NCT01431300?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2011-08. Estimated completion is 2013-07.

What conditions does trial NCT01431300 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT01431300?

The interventions under investigation include: gadofosveset (DRUG).

Who is sponsoring clinical trial NCT01431300?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01431300 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01431300's enrollment target sits among peer trials

30 678th of 1090 higher than 363 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01431300, the US trial registry maintained by the National Library of Medicine. NCT01431300 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.